#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Clinically relevant photodynamic therapy ( PDT ) was introduced about 45 years ago as a novel means for selectively eradicating a variety of solid tumors via cytotoxic photochemistry .
2-1	16-26	Clinically	abstract[3]	new[3]	appos	2-6[0_3]
2-2	27-35	relevant	abstract[3]	new[3]	_	_
2-3	36-48	photodynamic	abstract|abstract[3]	new|new[3]	coref	18-21
2-4	49-56	therapy	abstract[3]	new[3]	_	_
2-5	57-58	(	_	_	_	_
2-6	59-62	PDT	abstract	giv	coref	3-6
2-7	63-64	)	_	_	_	_
2-8	65-68	was	_	_	_	_
2-9	69-79	introduced	_	_	_	_
2-10	80-85	about	time[5]	new[5]	_	_
2-11	86-88	45	time[5]	new[5]	_	_
2-12	89-94	years	time[5]	new[5]	_	_
2-13	95-98	ago	time[5]	new[5]	_	_
2-14	99-101	as	_	_	_	_
2-15	102-103	a	_	_	_	_
2-16	104-109	novel	_	_	_	_
2-17	110-115	means	_	_	_	_
2-18	116-119	for	_	_	_	_
2-19	120-131	selectively	_	_	_	_
2-20	132-143	eradicating	_	_	_	_
2-21	144-145	a	abstract[6]	new[6]	_	_
2-22	146-153	variety	abstract[6]	new[6]	_	_
2-23	154-156	of	abstract[6]	new[6]	_	_
2-24	157-162	solid	abstract[6]|object[7]	new[6]|new[7]	coref	7-16[52_7]
2-25	163-169	tumors	abstract[6]|object[7]	new[6]|new[7]	_	_
2-26	170-173	via	abstract[6]|object[7]	new[6]|new[7]	_	_
2-27	174-183	cytotoxic	abstract[6]|object[7]|abstract|abstract[9]	new[6]|new[7]|new|new[9]	_	_
2-28	184-198	photochemistry	abstract[6]|object[7]|abstract[9]	new[6]|new[7]|new[9]	_	_
2-29	199-200	.	_	_	_	_

#Text=As an anti-tumor modality , PDT is unique in requiring three components : a photosensitizing agent ( PS ) , PS-exciting light in the far-visible-to-near-infrared range , and molecular oxygen .
3-1	201-203	As	_	_	_	_
3-2	204-206	an	abstract[10]	new[10]	_	_
3-3	207-217	anti-tumor	abstract[10]	new[10]	_	_
3-4	218-226	modality	abstract[10]	new[10]	_	_
3-5	227-228	,	_	_	_	_
3-6	229-232	PDT	abstract	giv	coref	4-4
3-7	233-235	is	_	_	_	_
3-8	236-242	unique	_	_	_	_
3-9	243-245	in	_	_	_	_
3-10	246-255	requiring	_	_	_	_
3-11	256-261	three	quantity[12]	new[12]	_	_
3-12	262-272	components	quantity[12]	new[12]	_	_
3-13	273-274	:	_	_	_	_
3-14	275-276	a	person[14]	new[14]	_	_
3-15	277-293	photosensitizing	event|person[14]	new|new[14]	_	_
3-16	294-299	agent	person[14]	new[14]	_	_
3-17	300-301	(	_	_	_	_
3-18	302-304	PS	abstract	new	coref	4-1
3-19	305-306	)	_	_	_	_
3-20	307-308	,	_	_	_	_
3-21	309-320	PS-exciting	event|abstract[17]	new|new[17]	coref	6-33[0_17]
3-22	321-326	light	abstract[17]	new[17]	_	_
3-23	327-329	in	abstract[17]	new[17]	_	_
3-24	330-333	the	abstract[17]|abstract[18]	new[17]|new[18]	coref	16-14[125_18]
3-25	334-362	far-visible-to-near-infrared	abstract[17]|abstract[18]	new[17]|new[18]	_	_
3-26	363-368	range	abstract[17]|abstract[18]	new[17]|new[18]	_	_
3-27	369-370	,	_	_	_	_
3-28	371-374	and	_	_	_	_
3-29	375-384	molecular	substance[19]	new[19]	coref	4-10[0_19]
3-30	385-391	oxygen	substance[19]	new[19]	_	_
3-31	392-393	.	_	_	_	_

#Text=PS photoexcitation during PDT gives rise to cytotoxic reactive oxygen species ( ROS ) such as singlet oxygen ( 1O2 ) .
4-1	394-396	PS	abstract|abstract[21]	giv|new[21]	coref	5-1[30_0]
4-2	397-412	photoexcitation	abstract[21]	new[21]	_	_
4-3	413-419	during	abstract[21]	new[21]	_	_
4-4	420-423	PDT	abstract[21]|abstract	new[21]|giv	coref	5-9
4-5	424-429	gives	_	_	_	_
4-6	430-434	rise	event[23]	new[23]	_	_
4-7	435-437	to	event[23]	new[23]	_	_
4-8	438-447	cytotoxic	event[23]|animal[25]	new[23]|new[25]	_	_
4-9	448-456	reactive	event[23]|animal[25]	new[23]|new[25]	_	_
4-10	457-463	oxygen	event[23]|substance|animal[25]	new[23]|giv|new[25]	coref	4-17[28_0]
4-11	464-471	species	event[23]|animal[25]	new[23]|new[25]	_	_
4-12	472-473	(	_	_	_	_
4-13	474-477	ROS	substance	new	_	_
4-14	478-479	)	_	_	_	_
4-15	480-484	such	_	_	_	_
4-16	485-487	as	_	_	_	_
4-17	488-495	singlet	substance|substance[28]	new|giv[28]	appos	4-20[0_28]
4-18	496-502	oxygen	substance[28]	giv[28]	_	_
4-19	503-504	(	_	_	_	_
4-20	505-508	1O2	substance	giv	coref	15-27
4-21	509-510	)	_	_	_	_
4-22	511-512	.	_	_	_	_

#Text=The first PS to receive FDA approval for PDT applications was Photofrin® , an oligomeric form of hematoporphyrin that continues to be used for a variety of malignancies .
5-1	513-516	The	abstract[30]	giv[30]	coref	5-12[0_30]
5-2	517-522	first	abstract[30]	giv[30]	_	_
5-3	523-525	PS	abstract[30]	giv[30]	_	_
5-4	526-528	to	_	_	_	_
5-5	529-536	receive	_	_	_	_
5-6	537-540	FDA	event[31]	new[31]	_	_
5-7	541-549	approval	event[31]	new[31]	_	_
5-8	550-553	for	_	_	_	_
5-9	554-557	PDT	abstract|abstract[33]	giv|new[33]	coref	6-8
5-10	558-570	applications	abstract[33]	new[33]	_	_
5-11	571-574	was	_	_	_	_
5-12	575-585	Photofrin®	abstract	giv	appos	5-14[35_0]
5-13	586-587	,	_	_	_	_
5-14	588-590	an	abstract[35]	giv[35]	coref	8-9[0_35]
5-15	591-601	oligomeric	abstract[35]	giv[35]	_	_
5-16	602-606	form	abstract[35]	giv[35]	_	_
5-17	607-609	of	abstract[35]	giv[35]	_	_
5-18	610-625	hematoporphyrin	abstract[35]|substance	giv[35]|new	_	_
5-19	626-630	that	_	_	_	_
5-20	631-640	continues	_	_	_	_
5-21	641-643	to	_	_	_	_
5-22	644-646	be	_	_	_	_
5-23	647-651	used	_	_	_	_
5-24	652-655	for	_	_	_	_
5-25	656-657	a	abstract[37]	new[37]	_	_
5-26	658-665	variety	abstract[37]	new[37]	_	_
5-27	666-668	of	abstract[37]	new[37]	_	_
5-28	669-681	malignancies	abstract[37]|abstract	new[37]|new	_	_
5-29	682-683	.	_	_	_	_

#Text=Unlike more conventional chemotherapy or radiotherapy , PDT has few ( if any ) light-independent side effects and is non-invasive and site-specific , i. e. , limited to the tumor upon which light is directed , typically via fiber optic networks .
6-1	684-690	Unlike	_	_	_	_
6-2	691-695	more	abstract[39]	new[39]	coref	12-13[0_39]
6-3	696-708	conventional	abstract[39]	new[39]	_	_
6-4	709-721	chemotherapy	abstract[39]	new[39]	_	_
6-5	722-724	or	_	_	_	_
6-6	725-737	radiotherapy	abstract	new	coref	12-11
6-7	738-739	,	_	_	_	_
6-8	740-743	PDT	abstract	giv	coref	7-3
6-9	744-747	has	_	_	_	_
6-10	748-751	few	_	_	_	_
6-11	752-753	(	_	_	_	_
6-12	754-756	if	_	_	_	_
6-13	757-760	any	abstract[43]	new[43]	coref	17-4[135_43]
6-14	761-762	)	abstract[43]	new[43]	_	_
6-15	763-780	light-independent	abstract[42]|abstract[43]	new[42]|new[43]	_	_
6-16	781-785	side	abstract[42]|abstract[43]	new[42]|new[43]	_	_
6-17	786-793	effects	abstract[43]	new[43]	_	_
6-18	794-797	and	abstract[43]	new[43]	_	_
6-19	798-800	is	abstract[43]	new[43]	_	_
6-20	801-813	non-invasive	abstract[43]	new[43]	_	_
6-21	814-817	and	abstract[43]	new[43]	_	_
6-22	818-831	site-specific	abstract[43]	new[43]	_	_
6-23	832-833	,	abstract[43]	new[43]	_	_
6-24	834-836	i.	abstract[43]	new[43]	_	_
6-25	837-839	e.	abstract[43]	new[43]	_	_
6-26	840-841	,	_	_	_	_
6-27	842-849	limited	_	_	_	_
6-28	850-852	to	_	_	_	_
6-29	853-856	the	abstract[44]	new[44]	coref	11-36[0_44]
6-30	857-862	tumor	abstract[44]	new[44]	_	_
6-31	863-867	upon	_	_	_	_
6-32	868-873	which	_	_	_	_
6-33	874-879	light	abstract	giv	_	_
6-34	880-882	is	_	_	_	_
6-35	883-891	directed	_	_	_	_
6-36	892-893	,	_	_	_	_
6-37	894-903	typically	place[48]	new[48]	_	_
6-38	904-907	via	place[48]	new[48]	_	_
6-39	908-913	fiber	substance|place[48]	new|new[48]	_	_
6-40	914-919	optic	substance|place[48]	new|new[48]	_	_
6-41	920-928	networks	place[48]	new[48]	_	_
6-42	929-930	.	_	_	_	_

#Text=Moreover , PDT can often overcome the innate or acquired resistance to other therapies that many tumors exhibit .
7-1	931-939	Moreover	_	_	_	_
7-2	940-941	,	_	_	_	_
7-3	942-945	PDT	abstract	giv	coref	11-7
7-4	946-949	can	_	_	_	_
7-5	950-955	often	_	_	_	_
7-6	956-964	overcome	_	_	_	_
7-7	965-968	the	abstract[50]	new[50]	coref	12-8[89_50]
7-8	969-975	innate	abstract[50]	new[50]	_	_
7-9	976-978	or	abstract[50]	new[50]	_	_
7-10	979-987	acquired	abstract[50]	new[50]	_	_
7-11	988-998	resistance	abstract[50]	new[50]	_	_
7-12	999-1001	to	abstract[50]	new[50]	_	_
7-13	1002-1007	other	abstract[50]|abstract[51]	new[50]|new[51]	_	_
7-14	1008-1017	therapies	abstract[50]|abstract[51]	new[50]|new[51]	_	_
7-15	1018-1022	that	_	_	_	_
7-16	1023-1027	many	object[52]	giv[52]	_	_
7-17	1028-1034	tumors	object[52]	giv[52]	_	_
7-18	1035-1042	exhibit	_	_	_	_
7-19	1043-1044	.	_	_	_	_

#Text=In addition to pre-existing administered sensitizers such as Photofrin® , pro-sensitizers have been developed , one common example being 5-aminolevulinic acid ( ALA ) .
8-1	1045-1047	In	_	_	_	_
8-2	1048-1056	addition	_	_	_	_
8-3	1057-1059	to	_	_	_	_
8-4	1060-1072	pre-existing	substance[53]	new[53]	_	_
8-5	1073-1085	administered	substance[53]	new[53]	_	_
8-6	1086-1097	sensitizers	substance[53]	new[53]	_	_
8-7	1098-1102	such	substance[53]	new[53]	_	_
8-8	1103-1105	as	substance[53]	new[53]	_	_
8-9	1106-1116	Photofrin®	substance[53]|abstract	new[53]|giv	coref	9-21[67_0]
8-10	1117-1118	,	_	_	_	_
8-11	1119-1134	pro-sensitizers	substance	new	_	_
8-12	1135-1139	have	_	_	_	_
8-13	1140-1144	been	_	_	_	_
8-14	1145-1154	developed	_	_	_	_
8-15	1155-1156	,	_	_	_	_
8-16	1157-1160	one	substance[56]	new[56]	coref	8-20[57_56]
8-17	1161-1167	common	substance[56]	new[56]	_	_
8-18	1168-1175	example	substance[56]	new[56]	_	_
8-19	1176-1181	being	_	_	_	_
8-20	1182-1198	5-aminolevulinic	substance[57]	giv[57]	coref	9-8[0_57]
8-21	1199-1203	acid	substance[57]	giv[57]	_	_
8-22	1204-1205	(	_	_	_	_
8-23	1206-1209	ALA	place	new	coref	9-11
8-24	1210-1211	)	_	_	_	_
8-25	1212-1213	.	_	_	_	_

#Text=Upon entering cancer cells via an amino acid transporter , ALA is metabolized to protoporphyrin IX ( PpIX ) , the active PS , via the heme biosynthetic pathway , PpIX accumulating initially in mitochondria .
9-1	1214-1218	Upon	_	_	_	_
9-2	1219-1227	entering	_	_	_	_
9-3	1228-1234	cancer	abstract|object[60]	new|new[60]	coref|coref	10-6[74_60]|12-2
9-4	1235-1240	cells	object[60]	new[60]	_	_
9-5	1241-1244	via	_	_	_	_
9-6	1245-1247	an	abstract[62]	new[62]	coref	13-15[100_62]
9-7	1248-1253	amino	abstract[62]	new[62]	_	_
9-8	1254-1258	acid	substance|abstract[62]	giv|new[62]	_	_
9-9	1259-1270	transporter	abstract[62]	new[62]	_	_
9-10	1271-1272	,	_	_	_	_
9-11	1273-1276	ALA	place	giv	coref	11-19
9-12	1277-1279	is	_	_	_	_
9-13	1280-1291	metabolized	_	_	_	_
9-14	1292-1294	to	_	_	_	_
9-15	1295-1309	protoporphyrin	person|quantity[65]	new|new[65]	_	_
9-16	1310-1312	IX	quantity[65]	new[65]	_	_
9-17	1313-1314	(	_	_	_	_
9-18	1315-1319	PpIX	object	new	coref	9-31
9-19	1320-1321	)	_	_	_	_
9-20	1322-1323	,	_	_	_	_
9-21	1324-1327	the	abstract[67]	giv[67]	coref	22-13[0_67]
9-22	1328-1334	active	abstract[67]	giv[67]	_	_
9-23	1335-1337	PS	abstract[67]	giv[67]	_	_
9-24	1338-1339	,	abstract[67]	giv[67]	_	_
9-25	1340-1343	via	abstract[67]	giv[67]	_	_
9-26	1344-1347	the	abstract[67]|abstract[70]	giv[67]|new[70]	_	_
9-27	1348-1352	heme	abstract[67]|abstract|abstract[70]	giv[67]|new|new[70]	coref	10-12
9-28	1353-1365	biosynthetic	abstract[67]|abstract|abstract[70]	giv[67]|new|new[70]	_	_
9-29	1366-1373	pathway	abstract[67]|abstract[70]	giv[67]|new[70]	_	_
9-30	1374-1375	,	_	_	_	_
9-31	1376-1380	PpIX	substance	giv	coref	13-11[98_0]
9-32	1381-1393	accumulating	_	_	_	_
9-33	1394-1403	initially	_	_	_	_
9-34	1404-1406	in	_	_	_	_
9-35	1407-1419	mitochondria	place	new	_	_
9-36	1420-1421	.	_	_	_	_

#Text=For rapid proliferative needs , tumor cells are more active in heme synthesis than normal counterparts .
10-1	1422-1425	For	_	_	_	_
10-2	1426-1431	rapid	abstract[73]	new[73]	_	_
10-3	1432-1445	proliferative	abstract[73]	new[73]	_	_
10-4	1446-1451	needs	abstract[73]	new[73]	_	_
10-5	1452-1453	,	_	_	_	_
10-6	1454-1459	tumor	object[74]	giv[74]	coref	12-1[87_74]
10-7	1460-1465	cells	object[74]	giv[74]	_	_
10-8	1466-1469	are	_	_	_	_
10-9	1470-1474	more	_	_	_	_
10-10	1475-1481	active	_	_	_	_
10-11	1482-1484	in	_	_	_	_
10-12	1485-1489	heme	abstract|abstract[76]	giv|new[76]	_	_
10-13	1490-1499	synthesis	abstract[76]	new[76]	_	_
10-14	1500-1504	than	abstract[76]	new[76]	_	_
10-15	1505-1511	normal	abstract[76]|abstract[77]	new[76]|new[77]	_	_
10-16	1512-1524	counterparts	abstract[76]|abstract[77]	new[76]|new[77]	_	_
10-17	1525-1526	.	_	_	_	_

#Text=In addition to acting as a PDT sensitizer , ALA-induced PpIX , like that induced by more lipophilic ALA esters , e. g. , Hexvix , can serve as a highly effective fluorophore for image-guided tumor resection .
11-1	1527-1529	In	_	_	_	_
11-2	1530-1538	addition	_	_	_	_
11-3	1539-1541	to	_	_	_	_
11-4	1542-1548	acting	_	_	_	_
11-5	1549-1551	as	_	_	_	_
11-6	1552-1553	a	_	_	_	_
11-7	1554-1557	PDT	abstract	giv	coref	12-18
11-8	1558-1568	sensitizer	_	_	_	_
11-9	1569-1570	,	_	_	_	_
11-10	1571-1582	ALA-induced	object[79]	new[79]	coref	18-25[150_79]
11-11	1583-1587	PpIX	object[79]	new[79]	_	_
11-12	1588-1589	,	_	_	_	_
11-13	1590-1594	like	_	_	_	_
11-14	1595-1599	that	_	_	_	_
11-15	1600-1607	induced	_	_	_	_
11-16	1608-1610	by	_	_	_	_
11-17	1611-1615	more	abstract[81]	new[81]	appos	11-22[82_81]
11-18	1616-1626	lipophilic	abstract[81]	new[81]	_	_
11-19	1627-1630	ALA	place|abstract[81]	giv|new[81]	_	_
11-20	1631-1637	esters	abstract[81]	new[81]	_	_
11-21	1638-1639	,	_	_	_	_
11-22	1640-1642	e.	object[82]	giv[82]	appos	11-25[0_82]
11-23	1643-1645	g.	object[82]	giv[82]	_	_
11-24	1646-1647	,	_	_	_	_
11-25	1648-1654	Hexvix	object	giv	coref	15-41[117_0]
11-26	1655-1656	,	_	_	_	_
11-27	1657-1660	can	_	_	_	_
11-28	1661-1666	serve	_	_	_	_
11-29	1667-1669	as	_	_	_	_
11-30	1670-1671	a	_	_	_	_
11-31	1672-1678	highly	_	_	_	_
11-32	1679-1688	effective	_	_	_	_
11-33	1689-1700	fluorophore	_	_	_	_
11-34	1701-1704	for	_	_	_	_
11-35	1705-1717	image-guided	event[85]	new[85]	_	_
11-36	1718-1723	tumor	abstract|event[85]	giv|new[85]	coref	22-2[174_0]
11-37	1724-1733	resection	event[85]	new[85]	_	_
11-38	1734-1735	.	_	_	_	_

#Text=Many cancer cells exhibit an intrinsic or acquired resistance to radiotherapy or chemotherapy , and resistance to PDT has also been demonstrated .
12-1	1736-1740	Many	object[87]	giv[87]	coref	15-39[116_87]
12-2	1741-1747	cancer	abstract|object[87]	giv|giv[87]	coref	16-38
12-3	1748-1753	cells	object[87]	giv[87]	_	_
12-4	1754-1761	exhibit	_	_	_	_
12-5	1762-1764	an	abstract[88]	new[88]	_	_
12-6	1765-1774	intrinsic	abstract[88]	new[88]	_	_
12-7	1775-1777	or	_	_	_	_
12-8	1778-1786	acquired	abstract[89]	giv[89]	coref	12-16[92_89]
12-9	1787-1797	resistance	abstract[89]	giv[89]	_	_
12-10	1798-1800	to	abstract[89]	giv[89]	_	_
12-11	1801-1813	radiotherapy	abstract[89]|abstract	giv[89]|giv	_	_
12-12	1814-1816	or	abstract[89]	giv[89]	_	_
12-13	1817-1829	chemotherapy	abstract[89]|abstract	giv[89]|giv	_	_
12-14	1830-1831	,	_	_	_	_
12-15	1832-1835	and	_	_	_	_
12-16	1836-1846	resistance	abstract[92]	giv[92]	coref	13-6[0_92]
12-17	1847-1849	to	abstract[92]	giv[92]	_	_
12-18	1850-1853	PDT	abstract[92]|abstract	giv[92]|giv	coref	23-23
12-19	1854-1857	has	_	_	_	_
12-20	1858-1862	also	_	_	_	_
12-21	1863-1867	been	_	_	_	_
12-22	1868-1880	demonstrated	_	_	_	_
12-23	1881-1882	.	_	_	_	_

#Text=For ALA-PDT , one notable resistance mechanism involves efflux of newly synthesized PpIX via the plasma membrane transporter ABCG2 .
13-1	1883-1886	For	_	_	_	_
13-2	1887-1894	ALA-PDT	substance	new	_	_
13-3	1895-1896	,	_	_	_	_
13-4	1897-1900	one	abstract[96]	new[96]	coref	14-1[101_96]
13-5	1901-1908	notable	abstract[96]	new[96]	_	_
13-6	1909-1919	resistance	abstract|abstract[96]	giv|new[96]	coref	16-33[131_0]
13-7	1920-1929	mechanism	abstract[96]	new[96]	_	_
13-8	1930-1938	involves	_	_	_	_
13-9	1939-1945	efflux	event[97]	new[97]	_	_
13-10	1946-1948	of	event[97]	new[97]	_	_
13-11	1949-1954	newly	event[97]|object[98]	new[97]|giv[98]	_	_
13-12	1955-1966	synthesized	event[97]|object[98]	new[97]|giv[98]	_	_
13-13	1967-1971	PpIX	event[97]|object[98]	new[97]|giv[98]	_	_
13-14	1972-1975	via	event[97]|object[98]	new[97]|giv[98]	_	_
13-15	1976-1979	the	event[97]|object[98]|abstract[100]	new[97]|giv[98]|giv[100]	_	_
13-16	1980-1986	plasma	event[97]|object[98]|abstract[100]	new[97]|giv[98]|giv[100]	_	_
13-17	1987-1995	membrane	event[97]|object[98]|animal|abstract[100]	new[97]|giv[98]|new|giv[100]	_	_
13-18	1996-2007	transporter	event[97]|object[98]|abstract[100]	new[97]|giv[98]|giv[100]	_	_
13-19	2008-2013	ABCG2	event[97]|object[98]|abstract[100]	new[97]|giv[98]|giv[100]	_	_
13-20	2014-2015	.	_	_	_	_

#Text=Another important mechanism involves nitric oxide ( NO ) generated by constitutive and/or PDT stress-upregulated inducible nitric oxide synthase ( iNOS/NOS2 ) .
14-1	2016-2023	Another	abstract[101]	giv[101]	_	_
14-2	2024-2033	important	abstract[101]	giv[101]	_	_
14-3	2034-2043	mechanism	abstract[101]	giv[101]	_	_
14-4	2044-2052	involves	_	_	_	_
14-5	2053-2059	nitric	abstract|substance[103]	new|new[103]	coref|coref	14-17|14-18[0_103]
14-6	2060-2065	oxide	substance[103]	new[103]	_	_
14-7	2066-2067	(	_	_	_	_
14-8	2068-2070	NO	_	_	_	_
14-9	2071-2072	)	_	_	_	_
14-10	2073-2082	generated	_	_	_	_
14-11	2083-2085	by	_	_	_	_
14-12	2086-2098	constitutive	_	_	_	_
14-13	2099-2105	and/or	_	_	_	_
14-14	2106-2109	PDT	_	_	_	_
14-15	2110-2128	stress-upregulated	_	_	_	_
14-16	2129-2138	inducible	_	_	_	_
14-17	2139-2145	nitric	abstract	giv	_	_
14-18	2146-2151	oxide	substance	giv	_	_
14-19	2152-2160	synthase	_	_	_	_
14-20	2161-2162	(	_	_	_	_
14-21	2163-2172	iNOS/NOS2	place	new	_	_
14-22	2173-2174	)	_	_	_	_
14-23	2175-2176	.	_	_	_	_

#Text=NO is a bioactive free radical molecule ( 1 – 2 sec lifetime in water ) that diffuses freely on its own and , similar to oxygen ( O2 ) , tends to partition into hydrophobic regions of cells , e. g. , cell membranes .
15-1	2177-2179	NO	_	_	_	_
15-2	2180-2182	is	_	_	_	_
15-3	2183-2184	a	substance[107]	new[107]	_	_
15-4	2185-2194	bioactive	substance[107]	new[107]	_	_
15-5	2195-2199	free	substance[107]	new[107]	_	_
15-6	2200-2207	radical	substance[107]	new[107]	_	_
15-7	2208-2216	molecule	substance[107]	new[107]	_	_
15-8	2217-2218	(	_	_	_	_
15-9	2219-2220	1	abstract[110]	new[110]	_	_
15-10	2221-2222	–	abstract[110]	new[110]	_	_
15-11	2223-2224	2	quantity|abstract[110]	new|new[110]	_	_
15-12	2225-2228	sec	person|abstract[110]	new|new[110]	_	_
15-13	2229-2237	lifetime	abstract[110]	new[110]	_	_
15-14	2238-2240	in	abstract[110]	new[110]	_	_
15-15	2241-2246	water	abstract[110]|substance	new[110]|new	ana	15-21
15-16	2247-2248	)	_	_	_	_
15-17	2249-2253	that	_	_	_	_
15-18	2254-2262	diffuses	_	_	_	_
15-19	2263-2269	freely	_	_	_	_
15-20	2270-2272	on	_	_	_	_
15-21	2273-2276	its	substance	giv	_	_
15-22	2277-2280	own	_	_	_	_
15-23	2281-2284	and	_	_	_	_
15-24	2285-2286	,	_	_	_	_
15-25	2287-2294	similar	_	_	_	_
15-26	2295-2297	to	_	_	_	_
15-27	2298-2304	oxygen	substance	giv	appos	15-29
15-28	2305-2306	(	_	_	_	_
15-29	2307-2309	O2	substance	giv	_	_
15-30	2310-2311	)	_	_	_	_
15-31	2312-2313	,	_	_	_	_
15-32	2314-2319	tends	_	_	_	_
15-33	2320-2322	to	_	_	_	_
15-34	2323-2332	partition	_	_	_	_
15-35	2333-2337	into	_	_	_	_
15-36	2338-2349	hydrophobic	place[115]	new[115]	_	_
15-37	2350-2357	regions	place[115]	new[115]	_	_
15-38	2358-2360	of	place[115]	new[115]	_	_
15-39	2361-2366	cells	place[115]|object[116]	new[115]|giv[116]	coref	16-36[133_116]
15-40	2367-2368	,	place[115]|object[116]	new[115]|giv[116]	_	_
15-41	2369-2371	e.	place[115]|object[116]|place[117]	new[115]|giv[116]|giv[117]	coref	16-9[0_117]
15-42	2372-2374	g.	place[115]|object[116]|place[117]	new[115]|giv[116]|giv[117]	_	_
15-43	2375-2376	,	place[115]|object[116]	new[115]|giv[116]	_	_
15-44	2377-2381	cell	place[115]|object[116]|place|place[119]	new[115]|giv[116]|new|new[119]	coref	18-10
15-45	2382-2391	membranes	place[115]|object[116]|place[119]	new[115]|giv[116]|new[119]	_	_
15-46	2392-2393	.	_	_	_	_

#Text=At relatively low steady state levels ( e. g. , 50 – 300 nM range ) , NO is known to play a key signaling role in survival , migration , and drug resistance of many different cancer cells .
16-1	2394-2396	At	_	_	_	_
16-2	2397-2407	relatively	abstract[121]	new[121]	_	_
16-3	2408-2411	low	abstract[121]	new[121]	_	_
16-4	2412-2418	steady	abstract[121]	new[121]	_	_
16-5	2419-2424	state	abstract|abstract[121]	new|new[121]	_	_
16-6	2425-2431	levels	abstract[121]	new[121]	_	_
16-7	2432-2433	(	_	_	_	_
16-8	2434-2436	e.	_	_	_	_
16-9	2437-2439	g.	place	giv	coref	17-26[140_0]
16-10	2440-2441	,	_	_	_	_
16-11	2442-2444	50	_	_	_	_
16-12	2445-2446	–	_	_	_	_
16-13	2447-2450	300	quantity	new	_	_
16-14	2451-2453	nM	quantity|abstract[125]	new|giv[125]	_	_
16-15	2454-2459	range	abstract[125]	giv[125]	_	_
16-16	2460-2461	)	_	_	_	_
16-17	2462-2463	,	_	_	_	_
16-18	2464-2466	NO	_	_	_	_
16-19	2467-2469	is	_	_	_	_
16-20	2470-2475	known	_	_	_	_
16-21	2476-2478	to	_	_	_	_
16-22	2479-2483	play	_	_	_	_
16-23	2484-2485	a	abstract[127]	new[127]	_	_
16-24	2486-2489	key	abstract[127]	new[127]	_	_
16-25	2490-2499	signaling	abstract|abstract[127]	new|new[127]	_	_
16-26	2500-2504	role	abstract[127]	new[127]	_	_
16-27	2505-2507	in	abstract[127]	new[127]	_	_
16-28	2508-2516	survival	abstract[127]|event	new[127]|new	_	_
16-29	2517-2518	,	abstract[127]	new[127]	_	_
16-30	2519-2528	migration	abstract[127]|event	new[127]|new	_	_
16-31	2529-2530	,	abstract[127]	new[127]	_	_
16-32	2531-2534	and	abstract[127]	new[127]	_	_
16-33	2535-2539	drug	abstract[127]|substance|abstract[131]	new[127]|new|giv[131]	ana	17-1[0_131]
16-34	2540-2550	resistance	abstract[127]|abstract[131]	new[127]|giv[131]	_	_
16-35	2551-2553	of	abstract[127]|abstract[131]	new[127]|giv[131]	_	_
16-36	2554-2558	many	abstract[127]|abstract[131]|object[133]	new[127]|giv[131]|giv[133]	coref	19-10[0_133]
16-37	2559-2568	different	abstract[127]|abstract[131]|object[133]	new[127]|giv[131]|giv[133]	_	_
16-38	2569-2575	cancer	abstract[127]|abstract[131]|abstract|object[133]	new[127]|giv[131]|giv|giv[133]	coref	18-9
16-39	2576-2581	cells	abstract[127]|abstract[131]|object[133]	new[127]|giv[131]|giv[133]	_	_
16-40	2582-2583	.	_	_	_	_

#Text=This contrasts with the cytotoxic effects of NO produced at much higher levels ( ≥1 µM ) by activated macrophages during an inflammatory response , e. g. , to infection .
17-1	2584-2588	This	abstract	giv	_	_
17-2	2589-2598	contrasts	_	_	_	_
17-3	2599-2603	with	_	_	_	_
17-4	2604-2607	the	abstract[135]	giv[135]	coref	23-11[187_135]
17-5	2608-2617	cytotoxic	abstract[135]	giv[135]	_	_
17-6	2618-2625	effects	abstract[135]	giv[135]	_	_
17-7	2626-2628	of	_	_	_	_
17-8	2629-2631	NO	_	_	_	_
17-9	2632-2640	produced	_	_	_	_
17-10	2641-2643	at	_	_	_	_
17-11	2644-2648	much	quantity[136]	new[136]	appos	17-15[137_136]
17-12	2649-2655	higher	quantity[136]	new[136]	_	_
17-13	2656-2662	levels	quantity[136]	new[136]	_	_
17-14	2663-2664	(	_	_	_	_
17-15	2665-2667	≥1	quantity[137]	giv[137]	_	_
17-16	2668-2670	µM	quantity[137]	giv[137]	_	_
17-17	2671-2672	)	_	_	_	_
17-18	2673-2675	by	_	_	_	_
17-19	2676-2685	activated	substance[138]	new[138]	_	_
17-20	2686-2697	macrophages	substance[138]	new[138]	_	_
17-21	2698-2704	during	substance[138]	new[138]	_	_
17-22	2705-2707	an	substance[138]|abstract[139]	new[138]|new[139]	coref	21-12[172_139]
17-23	2708-2720	inflammatory	substance[138]|abstract[139]	new[138]|new[139]	_	_
17-24	2721-2729	response	substance[138]|abstract[139]	new[138]|new[139]	_	_
17-25	2730-2731	,	_	_	_	_
17-26	2732-2734	e.	abstract[140]	giv[140]	_	_
17-27	2735-2737	g.	abstract[140]	giv[140]	_	_
17-28	2738-2739	,	_	_	_	_
17-29	2740-2742	to	_	_	_	_
17-30	2743-2752	infection	event	new	_	_
17-31	2753-2754	.	_	_	_	_

#Text=In previous work , we discovered that various cancer cell lines significantly upregulate cytoprotective iNOS and NO after a moderate photodynamic challenge sensitized by ALA-induced PpIX .
18-1	2755-2757	In	_	_	_	_
18-2	2758-2766	previous	abstract[142]	new[142]	_	_
18-3	2767-2771	work	abstract[142]	new[142]	_	_
18-4	2772-2773	,	_	_	_	_
18-5	2774-2776	we	person	acc	ana	21-1
18-6	2777-2787	discovered	_	_	_	_
18-7	2788-2792	that	_	_	_	_
18-8	2793-2800	various	abstract[146]	new[146]	coref	24-11[196_146]
18-9	2801-2807	cancer	abstract|abstract[146]	giv|new[146]	coref	23-2[182_0]
18-10	2808-2812	cell	place|abstract[146]	giv|new[146]	_	_
18-11	2813-2818	lines	abstract[146]	new[146]	_	_
18-12	2819-2832	significantly	_	_	_	_
18-13	2833-2843	upregulate	_	_	_	_
18-14	2844-2858	cytoprotective	abstract[147]	new[147]	coref	20-27[0_147]
18-15	2859-2863	iNOS	abstract[147]	new[147]	_	_
18-16	2864-2867	and	_	_	_	_
18-17	2868-2870	NO	_	_	_	_
18-18	2871-2876	after	_	_	_	_
18-19	2877-2878	a	event[149]	new[149]	_	_
18-20	2879-2887	moderate	event[149]	new[149]	_	_
18-21	2888-2900	photodynamic	substance|event[149]	giv|new[149]	_	_
18-22	2901-2910	challenge	event[149]	new[149]	_	_
18-23	2911-2921	sensitized	_	_	_	_
18-24	2922-2924	by	_	_	_	_
18-25	2925-2936	ALA-induced	abstract[150]	giv[150]	_	_
18-26	2937-2941	PpIX	abstract[150]	giv[150]	_	_
18-27	2942-2943	.	_	_	_	_

#Text=The iNOS/NO induction in PDT-surviving ( still attached ) cells was relatively rapid after irradiation ( 2 – 3 h ) and prolonged ( at least 24 h ) .
19-1	2944-2947	The	event[152]	new[152]	_	_
19-2	2948-2955	iNOS/NO	place|event[152]	new|new[152]	_	_
19-3	2956-2965	induction	event[152]	new[152]	_	_
19-4	2966-2968	in	event[152]	new[152]	_	_
19-5	2969-2982	PDT-surviving	event[152]|place	new[152]|new	_	_
19-6	2983-2984	(	_	_	_	_
19-7	2985-2990	still	_	_	_	_
19-8	2991-2999	attached	_	_	_	_
19-9	3000-3001	)	_	_	_	_
19-10	3002-3007	cells	object	giv	coref	20-3[159_0]
19-11	3008-3011	was	_	_	_	_
19-12	3012-3022	relatively	_	_	_	_
19-13	3023-3028	rapid	_	_	_	_
19-14	3029-3034	after	_	_	_	_
19-15	3035-3046	irradiation	abstract[155]	new[155]	_	_
19-16	3047-3048	(	abstract[155]	new[155]	_	_
19-17	3049-3050	2	abstract[155]	new[155]	_	_
19-18	3051-3052	–	abstract[155]	new[155]	_	_
19-19	3053-3054	3	abstract[155]|quantity	new[155]|new	_	_
19-20	3055-3056	h	abstract[155]|quantity	new[155]|new	coref	19-26[158_0]
19-21	3057-3058	)	abstract[155]	new[155]	_	_
19-22	3059-3062	and	_	_	_	_
19-23	3063-3072	prolonged	_	_	_	_
19-24	3073-3074	(	_	_	_	_
19-25	3075-3077	at	_	_	_	_
19-26	3078-3083	least	quantity[158]	giv[158]	_	_
19-27	3084-3086	24	quantity[158]	giv[158]	_	_
19-28	3087-3088	h	quantity[158]	giv[158]	_	_
19-29	3089-3090	)	_	_	_	_
19-30	3091-3092	.	_	_	_	_

#Text=Importantly , these cells exhibited a more aggressive growth , migratory , and invasive phenotype than non-photostressed controls , and this was suppressed by inhibition of iNOS or by NO scavenging .
20-1	3093-3104	Importantly	_	_	_	_
20-2	3105-3106	,	_	_	_	_
20-3	3107-3112	these	object[159]	giv[159]	coref	21-6[170_159]
20-4	3113-3118	cells	object[159]	giv[159]	_	_
20-5	3119-3128	exhibited	_	_	_	_
20-6	3129-3130	a	abstract[160]	new[160]	_	_
20-7	3131-3135	more	abstract[160]	new[160]	_	_
20-8	3136-3146	aggressive	abstract[160]	new[160]	_	_
20-9	3147-3153	growth	abstract[160]	new[160]	_	_
20-10	3154-3155	,	_	_	_	_
20-11	3156-3165	migratory	_	_	_	_
20-12	3166-3167	,	_	_	_	_
20-13	3168-3171	and	_	_	_	_
20-14	3172-3180	invasive	abstract[161]	new[161]	ana	20-21[0_161]
20-15	3181-3190	phenotype	abstract[161]	new[161]	_	_
20-16	3191-3195	than	abstract[161]	new[161]	_	_
20-17	3196-3213	non-photostressed	abstract[161]|event[162]	new[161]|new[162]	_	_
20-18	3214-3222	controls	abstract[161]|event[162]	new[161]|new[162]	_	_
20-19	3223-3224	,	_	_	_	_
20-20	3225-3228	and	_	_	_	_
20-21	3229-3233	this	abstract	giv	_	_
20-22	3234-3237	was	_	_	_	_
20-23	3238-3248	suppressed	_	_	_	_
20-24	3249-3251	by	_	_	_	_
20-25	3252-3262	inhibition	abstract[164]	new[164]	_	_
20-26	3263-3265	of	abstract[164]	new[164]	_	_
20-27	3266-3270	iNOS	abstract[164]|abstract	new[164]|giv	_	_
20-28	3271-3273	or	_	_	_	_
20-29	3274-3276	by	_	_	_	_
20-30	3277-3279	NO	abstract[166]	new[166]	_	_
20-31	3280-3290	scavenging	abstract[166]	new[166]	_	_
20-32	3291-3292	.	_	_	_	_

#Text=We postulated that induced diffusible NO from PDT-targeted cells might elicit a pro-growth/migratory response in non- or minimally-targeted bystander cells .
21-1	3293-3295	We	person	giv	ana	23-8
21-2	3296-3306	postulated	_	_	_	_
21-3	3307-3311	that	_	_	_	_
21-4	3312-3319	induced	_	_	_	_
21-5	3320-3330	diffusible	person	new	_	_
21-6	3331-3333	NO	object[170]	giv[170]	coref	21-16[173_170]
21-7	3334-3338	from	object[170]	giv[170]	_	_
21-8	3339-3351	PDT-targeted	object|object[170]	new|giv[170]	_	_
21-9	3352-3357	cells	object[170]	giv[170]	_	_
21-10	3358-3363	might	_	_	_	_
21-11	3364-3370	elicit	_	_	_	_
21-12	3371-3372	a	abstract[172]	giv[172]	_	_
21-13	3373-3393	pro-growth/migratory	place|abstract[172]	new|giv[172]	_	_
21-14	3394-3402	response	abstract[172]	giv[172]	_	_
21-15	3403-3405	in	abstract[172]	giv[172]	_	_
21-16	3406-3410	non-	abstract[172]|object[173]	giv[172]|giv[173]	coref	23-5[184_173]
21-17	3411-3413	or	abstract[172]|object[173]	giv[172]|giv[173]	_	_
21-18	3414-3432	minimally-targeted	abstract[172]|object[173]	giv[172]|giv[173]	_	_
21-19	3433-3442	bystander	abstract[172]|object[173]	giv[172]|giv[173]	_	_
21-20	3443-3448	cells	abstract[172]|object[173]	giv[172]|giv[173]	_	_
21-21	3449-3450	.	_	_	_	_

#Text=In an actual tumor , such targeting diversity might result from uneven PS distribution due to irregularities in the tumor microvasculature .
22-1	3451-3453	In	_	_	_	_
22-2	3454-3456	an	abstract[174]	giv[174]	coref	22-20[0_174]
22-3	3457-3463	actual	abstract[174]	giv[174]	_	_
22-4	3464-3469	tumor	abstract[174]	giv[174]	_	_
22-5	3470-3471	,	_	_	_	_
22-6	3472-3476	such	abstract[175]	new[175]	_	_
22-7	3477-3486	targeting	abstract[175]	new[175]	_	_
22-8	3487-3496	diversity	abstract[175]	new[175]	_	_
22-9	3497-3502	might	_	_	_	_
22-10	3503-3509	result	_	_	_	_
22-11	3510-3514	from	_	_	_	_
22-12	3515-3521	uneven	abstract[177]	new[177]	_	_
22-13	3522-3524	PS	abstract|abstract[177]	giv|new[177]	_	_
22-14	3525-3537	distribution	abstract[177]	new[177]	_	_
22-15	3538-3541	due	_	_	_	_
22-16	3542-3544	to	_	_	_	_
22-17	3545-3559	irregularities	abstract[178]	new[178]	_	_
22-18	3560-3562	in	abstract[178]	new[178]	_	_
22-19	3563-3566	the	abstract[178]|object[180]	new[178]|new[180]	_	_
22-20	3567-3572	tumor	abstract[178]|abstract|object[180]	new[178]|giv|new[180]	_	_
22-21	3573-3589	microvasculature	abstract[178]|object[180]	new[178]|new[180]	_	_
22-22	3590-3591	.	_	_	_	_

#Text=Using photosensitized prostate cancer PC3 cells , we recently observed NO-mediated hyper-aggressive bystander effects for the first time in the context of PDT .
23-1	3592-3597	Using	_	_	_	_
23-2	3598-3613	photosensitized	abstract[182]	giv[182]	coref	24-13[0_182]
23-3	3614-3622	prostate	place|abstract[182]	new|giv[182]	coref	24-26
23-4	3623-3629	cancer	abstract[182]	giv[182]	_	_
23-5	3630-3633	PC3	substance|object[184]	new|giv[184]	coref	24-26[204_0]
23-6	3634-3639	cells	object[184]	giv[184]	_	_
23-7	3640-3641	,	_	_	_	_
23-8	3642-3644	we	person	giv	ana	24-6
23-9	3645-3653	recently	_	_	_	_
23-10	3654-3662	observed	_	_	_	_
23-11	3663-3674	NO-mediated	abstract[187]	giv[187]	_	_
23-12	3675-3691	hyper-aggressive	abstract[187]	giv[187]	_	_
23-13	3692-3701	bystander	person|abstract[187]	new|giv[187]	_	_
23-14	3702-3709	effects	abstract[187]	giv[187]	_	_
23-15	3710-3713	for	abstract[187]	giv[187]	_	_
23-16	3714-3717	the	abstract[187]|time[188]	giv[187]|new[188]	_	_
23-17	3718-3723	first	abstract[187]|time[188]	giv[187]|new[188]	_	_
23-18	3724-3728	time	abstract[187]|time[188]	giv[187]|new[188]	_	_
23-19	3729-3731	in	abstract[187]|time[188]	giv[187]|new[188]	_	_
23-20	3732-3735	the	abstract[187]|time[188]|abstract[189]	giv[187]|new[188]|new[189]	_	_
23-21	3736-3743	context	abstract[187]|time[188]|abstract[189]	giv[187]|new[188]|new[189]	_	_
23-22	3744-3746	of	abstract[187]|time[188]|abstract[189]	giv[187]|new[188]|new[189]	_	_
23-23	3747-3750	PDT	abstract[187]|time[188]|abstract[189]|event	giv[187]|new[188]|new[189]|giv	_	_
23-24	3751-3752	.	_	_	_	_

#Text=In the present study , we compared the ability of four PDT-treated cancer lines ( melanoma BLM , glioblastoma U87 , breast MDA-MB-231 , and prostate PC3 ) to stimulate NO-dependent aggressiveness in bystander cells of the same type .
24-1	3753-3755	In	_	_	_	_
24-2	3756-3759	the	abstract[191]	new[191]	_	_
24-3	3760-3767	present	abstract[191]	new[191]	_	_
24-4	3768-3773	study	abstract[191]	new[191]	_	_
24-5	3774-3775	,	_	_	_	_
24-6	3776-3778	we	person	giv	_	_
24-7	3779-3787	compared	_	_	_	_
24-8	3788-3791	the	abstract[193]	new[193]	_	_
24-9	3792-3799	ability	abstract[193]	new[193]	_	_
24-10	3800-3802	of	abstract[193]	new[193]	_	_
24-11	3803-3807	four	abstract[193]|abstract[196]	new[193]|giv[196]	appos	24-16[199_196]
24-12	3808-3819	PDT-treated	abstract[193]|object|abstract[196]	new[193]|new|giv[196]	_	_
24-13	3820-3826	cancer	abstract[193]|abstract|abstract[196]	new[193]|giv|giv[196]	_	_
24-14	3827-3832	lines	abstract[193]|abstract[196]	new[193]|giv[196]	_	_
24-15	3833-3834	(	_	_	_	_
24-16	3835-3843	melanoma	abstract|object[198]|abstract[199]	new|new[198]|giv[199]	_	_
24-17	3844-3847	BLM	object[198]|abstract[199]	new[198]|giv[199]	_	_
24-18	3848-3849	,	abstract[199]	giv[199]	_	_
24-19	3850-3862	glioblastoma	abstract[199]|place[200]	giv[199]|new[200]	_	_
24-20	3863-3866	U87	abstract[199]|place[200]	giv[199]|new[200]	_	_
24-21	3867-3868	,	abstract[199]	giv[199]	_	_
24-22	3869-3875	breast	abstract[199]|place|object[202]	giv[199]|new|new[202]	_	_
24-23	3876-3886	MDA-MB-231	abstract[199]|object[202]	giv[199]|new[202]	_	_
24-24	3887-3888	,	abstract[199]	giv[199]	_	_
24-25	3889-3892	and	abstract[199]	giv[199]	_	_
24-26	3893-3901	prostate	abstract[199]|place|substance[204]	giv[199]|giv|giv[204]	_	_
24-27	3902-3905	PC3	abstract[199]|substance[204]	giv[199]|giv[204]	_	_
24-28	3906-3907	)	_	_	_	_
24-29	3908-3910	to	_	_	_	_
24-30	3911-3920	stimulate	_	_	_	_
24-31	3921-3933	NO-dependent	abstract[205]	new[205]	_	_
24-32	3934-3948	aggressiveness	abstract[205]	new[205]	_	_
24-33	3949-3951	in	abstract[205]	new[205]	_	_
24-34	3952-3961	bystander	abstract[205]|person[206]	new[205]|new[206]	_	_
24-35	3962-3967	cells	abstract[205]|person[206]	new[205]|new[206]	_	_
24-36	3968-3970	of	abstract[205]|person[206]	new[205]|new[206]	_	_
24-37	3971-3974	the	abstract[205]|person[206]|abstract[207]	new[205]|new[206]|new[207]	_	_
24-38	3975-3979	same	abstract[205]|person[206]|abstract[207]	new[205]|new[206]|new[207]	_	_
24-39	3980-3984	type	abstract[205]|person[206]|abstract[207]	new[205]|new[206]|new[207]	_	_
24-40	3985-3986	.	_	_	_	_
